Daiichi-Sanyo invests €17 million in its Altkirch plant

In an effort to double production for veterinary use, Daiichi-Sanyo, a Japanese pharmaceutical group, is committing to a €17 million investment until 2023 for its Altkirch plant in Alsace.

A two-phase project

The Altkirch plant, which specialises in the manufacture of active ingredients for drugs against joint diseases (osteoarthritis, phlebitis, contusions, etc.) from animal matter (cartilage from the trachea of oxen), will carry out the production increase in two phases, which will follow one another without interruption. The aim is to increase production for veterinary use to 2 tonnes per year. In addition, the investment is accompanied by job creation. In two years, Daiichi-Sankyo Altkirch has grown from 42 to 53 employees and the plant intends to further expand its workforce.

Discover Daiichi-Sanyo

Daiichi Sankyo is a Japanese global pharmaceutical company based in Tokyo, Japan, with operations in more than 50 countries.
Formed by the merger of Daiichi and Sankyo Laboratories in 2005, they are now one of the 25 largest pharmaceutical companies in the world with over 16,000 employees in 22 countries.